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Nootropics for Healthy Individuals 
Jin Pyo Jeon 
 
 
 With recent advances in fields like biotechnology and genetic engineering, the concern 
for a just and equal distribution of human enhancement technologies undoubtedly became one of 
the most significant ethical dilemmas of the 21st century. And with the sudden rise of cognitive 
enhancement drug (otherwise called as nootropics) use in society, the need for developing 
policies to address these dilemmas have now become an urgent issue that the scientific and 
political community must confront. Once only used by the few with special needs or 
neurological disorders, nootropics are now being utilized by a significant part of the population 
for cognitive enhancement, inciting a debate of the regulation and legalization of nootropics. 
Nonetheless, given the currently known benefits and risks of nootropics, the mechanisms through 
which nootropics function, and the ineffectiveness of policy restrictions, it would be more 
pragmatic to inform and allow for the non-prescription uses for some nootropics rather than to 
restrict its use.  
 
Benefits, Risks, and Viability of the Use of Nootropics 
 Among many other nootropics, two drugs have become the de facto nootropics for many 
healthy individuals: modafinil (commercially known as Provigil) and methylphenidate 
(commercially known as Ritalin). Used as prescribed, modafinil and methylphenidate have 
different purposes; modafinil is used to alleviate symptoms of “excessive daytime sleepiness”, 
while methylphenidate (MPH) is used for the treatment of attention-deficit hyperactivity disorder 
(Repantis et. al, 2010, p. 188). Despite these differences between the two, they are both 
frequently used for the singular purpose of improving the ability to complete a cognitive task.  
 Modafinil’s most significant effect, as it could be inferred by its primary use, is the 
promotion of wakefulness and the maintenance of cognitive capacity for those who are sleep-
deprived. This effect of modafinil have been used by military to stave off the inevitable cognitive 
decline of long missions (Repantis et. al, 2010, p. 188). In non-sleep-deprived individuals, 
Professor Repantis et al. found in his meta-analysis that modafinil promoted only the capacity to 
pay attention in the studies in which modafinil was consumed once (2010, p. 203). Another 
meta-analysis have found modafinil may enhance working memory (Lynch et al, 2012, p. 122), 
which is a “process whereby information is held in mind for brief periods” (Husain & Mehta, 
2011, p. 28). Beyond attention, another study have reported improvements in mood, memory for 
digits, pattern recognition, “spatial planning, and stop-signal reaction time” (Turner et al., 2002, 
p. 260). By contrast, there are studies that report contradictory results, with one study reporting 
that modafinil only raised the anxiety levels of the volunteers who took modafinil, and moreover 
with no cognitive enhancements (Randall et al., 2003, p. 163).  
 Like modafinil, effects of methylphenidate (MPH) can vary widely depending on the 
studies. And like modafinil, the primary mechanism and function of MPH is known; MPH 
primarily leads to the arousal of the person by increasing the levels of dopamine and 
noradrenaline, which is known to positively affect the spatial working memory (SWM) in 
monkeys (Mehta et al., 2000, p.  1). This arousal is also thought to lead to improvements in 
attention in theory, as the meta-analysis by Professor Lynch et al. has concluded (2011, p. 121). 
However, a study by Professor Elliott et al. have found that while there were no enhancements of 
attention, spatial working memory may be enhanced by MPH. The study also demonstrated the 
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intricate influences of MPH, showing that the MPH improved the performance of new tasks 
while it hindered the performance of familiar tasks (1996, p. 196).  
 While numerous benefits of modafinil and MPH have been observed in many different 
studies as shown above, the contradictions and discrepancies between the studies led Professor 
Cools and Robbins to conclude that the cognitive enhancements of nootropics are generally only 
modest across population (Cools & Robbins, 2004). However, many studies, including the study 
by Professor Cools, argue that the potential societal benefits of nootropics are much more 
significant than what the general cognitive benefits of nootropics may be for several reasons. 
First, Professor Cools states that there are significant individual variations of the effects of 
nootropics, which means that many people may derive significant cognitive benefits from 
nootropics despite the modest benefits across population. Another reason is the significance of 
non-cognitive effects of the nootropic. While some of the effects of nootropics might not be 
purely “cognitive”, these nootropic effect on mood and motivation are utilized by many to 
engage more with their cognitive tasks (Lynch. et al, 2011). For example, one study have found 
that MPH raised dopamine levels when the subjects were solving math problems, thus increasing 
the motivation to perform an academic task (Volkow et al., 2004, p. 1172). These three possible 
benefits of nootropics, when considered as a whole, are certainly a nudge towards the societal 
utilization of nootropics. 
 However, beyond its benefits, the risks of nootropic use must also be considered to make 
an optimal, informed decision. One contention against the use of nootropic is the possibility of 
increased nootropic use due to societal coercion. The argument suggests that once the nootropic 
use is legalized, people might feel compelled to take nootropics to maintain their competitive 
edge against others who take nootropics. That might be certainly true. However, psychology 
Professor Cakic in his article argues that that social coercion is the wrong factor to focus on. 
Instead, he states that social coercion is arguably harmful only if the nootropics themselves are 
harmful (Cakic, 2009, p. 613). Indeed, just as few might consider social coercion to use caffeine 
as a significant threat, social coercion for nootropics will not be a significant threat if nootropics 
are relatively harmless. And as current population studies seem to suggest that the use of 
nootropic like modafinil are mostly harmless (Cakic, 2009, p. 613), the fear of social coercion 
could be overblown.   
 Another risk involved with the nootropics legalization is the unestablished relationship 
between long-term nootropic use and academic performance. As nootropics are often used by 
students for academic purposes (Farrah et al, 2004), this risk is quite pertinent. While the 
nootropics do bring about cognitive enhancements and increase motivation to do academic work 
(Lynch. et al, 2011; Volkow et al., 2004, p. 1172), that does not necessarily mean that academic 
performance will improve with nootropics use. As many worry, students may be using 
nootropics as a clutch, relying solely on the effects of the nootropic to get through the studies. 
The findings of a survey of about 1500 German primary school and university students presents 
the hypothesis as a possibility. The survey have found that students with bad grades were more 
likely to use prescription stimulants as nootropics in the past month or in their lifetime (Franke 
et. al, 2010, p.65). This finding, the authors noted, matched with the findings of another study 
that have also found that the misuse of stimulants were associated with bad grades. However, 
these studies do not necessarily demonstrate a negative causal relationship between nootropic use 
and academic performance, nor are these studies flawless. As the authors of the study state, the 
study is not necessarily conclusive due to the possibility of response bias, unrepresentative 
homogenous population, and the failure to distinguish the frequency of the use (Franke et al, 
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2010, p. 65-66). However, these studies do emphasize a need for a study to investigate the 
nootropic effect on academic performance.  
Nootropics and Cognitive and Socioeconomic Equality 
 Among characteristics of nootropics stated above, individual variations of cognitive 
enhancement are thought to be a particularly powerful determinant of the effects of nootropics in 
many studies (Randall et. al., 2005; Cools & Robbins, 2004). And as these studies have found, 
baseline performance (performance prior to the experiment) is likely to be the cause of the 
variations, with lower baseline performance levels corresponding with greater cognitive benefits 
from nootropics and vice versa. This effect persisted through various types of cognitive 
performance, such as working memory, short-term memory, and attention (Randall et. al, 2005; 
Cools & Robbins, 2004). The mechanism behind such discrepancies, as Professor Cools and 
Robbins theorize, is the interaction between the optimal levels of neurotransmission and the 
nootropic’s influence on neurotransmitter activity (2005). As Cools and Robbins explain, the 
peak cognitive performance of an individual can only be achieved with an optimal level of 
neurotransmitter activity - and not with deficient nor excessive levels of activity. Thus, 
nootropic’s ability to increase neurotransmission within the brain may be beneficial for those 
who have lower than optimal level of brain activity and, by extension, neutral or even harmful to 
those whose neurotransmission levels are already at the optimal levels (2005). 
This phenomenon of neurotransmission levels and nootropics are not only pertinent to 
people with ADHD who are clinically diagnosed to have low levels of neurotransmitter activity, 
but also to “healthy” individuals that can reach a more optimal level of brain activity with 
nootropics. For these individuals, who may not meet one of the many criteria to be diagnosed as 
ADHD, nootropics may serve as a cognitive equalizer. By contrast, nootropic’s ineffectiveness 
for people who are already at their optimal neurotransmission levels serves as a relief for many 
who were concerned about nootropics creating “unfair” advantages. Ultimately, based on these 
mechanisms of nootropics, existing regulations and restrictions that limit access to nootropics 
may encourage greater cognitive disparity in the society.  
Furthermore, considering the typical users of nootropics in United States, regulations 
may further accentuate the socioeconomic disparity among the population. As neuroscientist 
Martha J. Farah et al. have observed, typical users of nootropic tend to be “college students, an 
overwhelmingly middle-class and privileged segment of the population” (2004, p. 423). 
Regulations play a role in this disparity of nootropic use by financially restricting people of 
lower socioeconomic status from accessing the costly prescription drugs. And if nootropics can 
significantly improve one’s academic or business performance, restrictions to nootropics may 
widen the wealth and the knowledge gap between the haves and have-nots. However, nootropics 
may also be used to bridge the gap; as Farah suggested, the relative ease of distributing 
nootropics compared to other neurocognitive enhancements, such as “good nutrition [and] high-
quality schools” (Farah et al, 2004, p. 423), may be utilized to reduce the gap. Therefore, the 
removal of the effective nootropic regulations may promote a greater cognitive and 
socioeconomic equality.  
Ineffectiveness of Nootropics Regulation and Possible Alternatives 
 Not only could regulations of nootropics possibly lead to cognitive and socioeconomic 
inequality, but it is also likely to be ineffective at reducing the use and the risks of nootropics. In 
his commentary, Professor Cakic compares the regulation of nootropics to that of the 
performance-enhancing drugs in athletics, which have largely been unsuccessful. Summarizing 
the study of Foddy and Savulescu, Professor Cakic argues that “any attempt to prohibit 
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performance-enhancing drugs is condemned to failure” (Cakic, 2009, p. 612). Furthermore, he 
states that the current, prevalent non-prescription use of controlled nootropics (like modafinil and  
MPH) already demonstrates that effective regulations on nootropics are impossible (Cakic, 2009, 
p. 612). 
So how should the government promote the safety of the people who opt to utilize 
nootropics?  One possibility is to hold public awareness campaigns about the benefits and risks 
of the nootropics. Currently, the lack of awareness of nootropic’s mechanisms may cause many 
to take nootropics, yet derive no significant cognitive enhancements other than the effects of 
placebo (Looby & Earleywine, 2011, p. 433). Furthermore, as stated above, nootropics may even 
inhibit some aspects of cognition or cause negative effects for those with high baseline cognitive 
performance (Randall et al., 2003, 2005; Cools & Robbins, 2004). Another possibility is to 
encourage more clinical studies on the long-term effects of nootropics. While the use of 
nootropics like modafinil have been observed and generally deemed as possessing low risk of 
harm, the lack of a rigorous clinical study makes the analysis of risks uncertain and hidden risks 
possible (Cakic, 2009, p. 613). Undoubtedly, the removal of the nootropic regulations will allow 
for a more rigorous and robust clinical trials, and thus better insure the safety of the people. 
Indeed, these alternatives would be much more beneficial compared to the ineffective regulation.      
Summary 
While the benefits of cognitive enhancement drugs appear to be only moderate in large 
studies, the small risks of nootropics and the large individual variations of drug effectiveness 
suggests that the benefits of nootropic use may outweigh the risks for many individuals. In 
particular, the cognitive enhancements that nootropics can provide may help equalize the 
cognitive deficiencies that may incur due to genetic or environmental differences. Policy 
restrictions on nootropics may worsen the intellectual disparity between the people who have 
access to nootropics and those who do not, nor will it be effective in its purpose. Therefore, 
rather than to continue the ineffective regulations of nootropics, it might be a better choice to 
inform the public of the effective nootropics and their benefits and risks. 
As our society of “Information Age” face increasing demands for intellectual labor and 
diminishing demands for physical labor, it is inevitable that the societal qualities we value, such 
as socioeconomic equality and welfare, will be increasingly interlinked with our individual 
cognitive capacities. With such trend, it has undoubtedly become necessary for us to now 
consider the possibility of enhancing our cognition through these more potent nootropics. Indeed, 
just as we learned to utilize caffeine for their cognitive benefits, we would need to carefully 
consider if these emerging nootropics can be our next caffeine.  
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